

ASX ANNOUNCEMENT

3 July 2023

Reset Mind Sciences signs long-term lease for unique property incorporating office, clinic and GMP manufacturing



Little Green Pharma is pleased to announce its psychedelics focused subsidiary Reset Mind Sciences Ltd (**Reset**) has entered into a commercial lease agreement for a unique property that incorporates office, clinic and Good Manufacturing Practice (**GMP**) manufacturing facilities in the Perth suburb of Shenton Park.

The property provides a compelling strategic opportunity for Reset to bring the bulk of its operations together on one site as it continues to make strong progress in the rapidly emerging field of psychedelic medicines in Australia.

As Reset works towards its goal of producing GMP grade psilocybin, the property's GMP manufacturing facility provides sufficient capacity for all of Reset's expected requirements without the need for extensive fit out and therefore capital expenditure. The manufacturing facilities will require GMP certification for Reset's intended use, however the fit out has been done to the highest standards and was certified by the TGA for the previous tenant's operations. The Company has also acquired the Facility Validation Documentation related to the manufacturing facilities.

The property also incorporates a separate clinic component that will be fitted out for the specific requirements of treatment using psychedelic medicines. Reset has previously announced a strategic alliance with private health insurer HIF (refer ASX announcement dated 22 March 2023) to develop a proof-of-concept mental health care facility offering psychedelic assisted psychotherapy. Under the terms of that agreement, HIF has contributed \$250,000 towards the establishment of this facility. The property is also zoned as a potential mental health day hospital site.

The HIF agreement follows the announcement by the TGA allowing psychiatrists, under strictly defined parameters, to prescribe psilocybin for treatment resistant depression and MDMA for PTSD under the Authorised Prescriber scheme from 1 July 2023.



Reset CEO Mr Shaun Duffy said *“As the psychedelics industry continues to develop, Reset had a need for both GMP manufacturing capability and bespoke clinic facilities. This property presented an unexpected opportunity to meet both requirements and thereby future proof our business for the foreseeable future with only very modest capital expenditure requirements.”*

The lease commences on 1 July 2023 for an initial 5-year term with an option for a further 5-year extension thereafter. Given the lease value, the Company does not regard the lease as price sensitive.

ENDS

BY ORDER OF THE BOARD

Alistair Warren

Company Secretary



For further information please contact:

Alistair Warren
Company Secretary

Little Green Pharma
E: a.warren@lgp.global
T: +61 8 6280 0050

Shaun Duffy
Chief Executive Officer

Reset Mind Sciences
E: s.duffy@lgp.global
T: +61 (0)404 094 384

Fleta Solomon
Chief Executive Officer

Little Green Pharma
E: f.solomon@lgp.global
T: +61 8 6280 0050

About Little Green Pharma

Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, with its Danish facility being one of the largest GMP medicinal cannabis production sites in Europe (if not the largest) and its West Australia site a premium indoor GMP production facility specialising in premium hand-crafted cannabis strains.

Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: www.computershare.com.au/easyupdate/lgp